Collaborative Work. CYPRESS and OREXIGEN shall collaborate in the development of LICENSED PRODUCTS through assistance to be provided by OREXIGEN as outlined on APPENDIX B and referred to herein as the “COLLABORATIVE WORK PLAN”, which shall include the PRE-CLINICAL STUDIES and CLINICAL STRATEGY ASSISTANCE (the “COLLABORATIVE WORK”). The COLLABORATIVE WORK PLAN shall be updated by mutual agreement of OREXIGEN and CYPRESS within thirty (30) days of the date of this AGREEMENT. CYPRESS shall have final decision-making authority with regard to development and commercialization of LICENSED PRODUCTS, including, without limitation, whether to develop any LICENSED PRODUCTS for depression. OREXIGEN shall make all PRE-COLLABORATION OREXIGEN INTELLECTUAL PROPERTY and COLLABORATION OREXIGEN INTELLECTUAL PROPERTY available for review by CYPRESS. *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Appears in 2 contracts
Sources: License Agreement (Orexigen Therapeutics, Inc.), License Agreement (Orexigen Therapeutics, Inc.)